Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Operating Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has disclosed Operating Leases for 6 consecutive years, with $55.5 million as the latest value for Q1 2026.

  • Quarterly Operating Leases rose 177.49% to $55.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.5 million through Feb 2026, up 177.49% year-over-year, with the annual reading at $52.9 million for FY2025, 160.76% up from the prior year.
  • Operating Leases for Q1 2026 was $55.5 million at Nurix Therapeutics, up from $52.9 million in the prior quarter.
  • The five-year high for Operating Leases was $55.5 million in Q1 2026, with the low at $2.6 million in Q3 2023.
  • Average Operating Leases over 5 years is $19.9 million, with a median of $20.0 million recorded in 2025.
  • The sharpest move saw Operating Leases soared 679.33% in 2024, then plummeted 72.23% in 2025.
  • Over 5 years, Operating Leases stood at $6.4 million in 2022, then soared by 259.42% to $23.1 million in 2023, then decreased by 12.26% to $20.3 million in 2024, then soared by 160.76% to $52.9 million in 2025, then rose by 4.81% to $55.5 million in 2026.
  • According to Business Quant data, Operating Leases over the past three periods came in at $55.5 million, $52.9 million, and $52.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.